Are Skeletal Muscle Mass and Density Associated with Fatigue In Early-Stage Colorectal Cancer Patients?

Abstract Aim: Sarcopenia is a progressive and generalized syndrome that can be linked to many causes such as cancers, and is caused by a quantitative and qualitative disorder (loss of muscle strength and / or physical performance) of skeletal muscle mass. Although sarcopenia has some hypothetical explanation in clinical practice, the mechanisms underlying this condition have not been clearly differentiated in patients with cancer. We aimed to investigate the relationship between irisin and FGF21 in detecting sarcopenia in colorectal cancer patients.Material and Method: Current prospectively study included non-metastatic newly diagnosed colorectal cancer patients. Patients were divided into two groups of 25 people, those with and without sarcopenia. Body composition measurements by examined by BIA. To measure the level of iris and FGF21 from patients, blood samples were taken into the biochemistry tube and their levels were measured. Results: The median age of the patients included in the study was 60 years (range: 21-81), 68 % were men. It was found that there was a significant relationship between sarcopenia and gender and BMI measurement. When Spearman correlation analysis was performed between skeletal muscle mass index and FGF21, irisin and CRP, there was a positive correlation between skeletal muscle mass index and irisin and FGF21, while there was a negative correlation between skeletal muscle mass index and CRP. [respectively: (r: 0.282, p: 0.048), (r: 0.564, p: <0.001) and (r: -0.360, p: 0.010). Similar results were found between hand grip strength and FGF21, irisin and CRP. [respectively: (r: 0.342, p: 0.015), (r: 0.290, p: 0.041) and (r: -0.476, p <0.001)]. When sarcopenia was treated as the dependent variable in the logistic regression analysis, and FGF21, irisin, CRP, gender and BMI were treated as the independent variables, irisin and CRP levels were determined as independent predictors. Conclusion: This study was revealed that there is a negative relationship between sarcopenia and irisin and FGF-21 in operated non-metastatic colorectal cancer patients and there may be a relationship between sarcopenia and inflammation. It suggest that these biomarkers may play a role in the pathophysiology of sarcopenia. However, our results need to be validated in different types of cancer and with more patients.

Download Full-text

Preoperative evaluation of skeletal muscle mass in the risk assessment for the short‑term outcome of elderly colorectal cancer patients undergoing colectomy

Molecular and Clinical Oncology ◽

10.3892/mco.2018.1607 ◽

2018 ◽

Author(s):

Hiroshi Tamagawa ◽

Toru Aoyama ◽

Kenta Iguchi ◽

Hirohito Fujikawa ◽

Sho Sawazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Risk Assessment ◽

Skeletal Muscle ◽

Cancer Patients ◽

Skeletal Muscle Mass ◽

Preoperative Evaluation ◽

Short Term ◽

Term Outcome ◽

Short Term Outcome ◽

Colorectal Cancer Patients

Download Full-text

Clinical implications of low skeletal muscle mass in early-stage breast and colorectal cancer

Proceedings of The Nutrition Society ◽

10.1017/s0029665118000423 ◽

2018 ◽

Vol 77 (4) ◽

pp. 382-387 ◽

Cited By ~ 9

Author(s):

Elizabeth Cespedes Feliciano ◽

Wendy Y. Chen

Keyword(s):

Colorectal Cancer ◽

Skeletal Muscle ◽

Body Composition ◽

Muscle Mass ◽

Skeletal Muscle Mass ◽

Early Stage ◽

Metastatic Cancer ◽

Disease Free Survival ◽

Metastatic Breast ◽

Metastatic Setting

Although obesity has now been widely accepted to be an important risk factor for cancer survival, the associations between BMI and cancer mortality have not been consistently linear. Although morbid obesity has clearly been associated with worse survival, some studies have suggested a U-shaped association with no adverse association with overweight or lower levels of obesity. This ‘obesity paradox’ may be due to the fact that BMI likely incompletely captures key measures of body composition, including distribution of skeletal muscle and adipose tissue. Fat and lean body mass can be measured using clinically acquired computed tomography scans. Many of the earlier studies focused on patients with metastatic cancer. However, skeletal muscle loss in the metastatic setting may reflect end-stage disease processes. Therefore, this article focuses on the clinical implication of low skeletal muscle mass in early-stage non-metastatic breast and colorectal cancer where measures of body composition have been shown to be strong predictors of disease-free survival and overall survival and also chemotherapy toxicity and operative risk.

Download Full-text